Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 5,852

Document Document Title
WO/2018/178142A1
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...  
WO/2018/172133A1
Compounds of formula (I), wherein the subsitiuents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to t...  
WO/2018/172026A1
The invention relates to a process for synthesizing an aqueous N,N-dimethyl glucamine solution, characterized in that a formaldehyde solution is metered into an N-methyl glucamine solution in the presence of a metal catalyst at hydrogen ...  
WO/2018/172025A1
The invention relates to a method for preparing aqueous solutions of N,N-dimethylglucamine, characterized by first preparing an adduct of N-methylglucamine and formaldehyde in water at temperatures of between 15°C and 40°C, and subsequ...  
WO/2018/148113A1
The present invention is directed to 13C and/or 2H isotope enhanced ambroxol ("isotope enhanced ambroxol") and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditi...  
WO/2018/143923A1
The present disclosure is drawn to an amine synergist including a tertiary benzylamine with a substituted benzene ring attached to a tertiary amine. The tertiary amine can be modified with multiple water soluble groups.  
WO/2018/135506A1
The purpose of the present invention is to provide a ruthenium complex which is capable of serving as a reduction catalyst that is applicable to an industrial production. According to the present invention, ketones, aldehydes, esters or ...  
WO/2018/129609A1
Compounds of formula (II) are useful in modulating voltage-gated sodium channel activity. Their preparation and use for reducing the severity of convulsant activity in a subject, for example in the treatment of epilepsy, is presented.  
WO/2018/127806A1
The present invention provides a process for preparation of isoproterenol hydrochloride (1a) comprising catalytic hydrogenation of 3',4'-dihydroxy-2-(isopropylamino)-acetophenone hydrochloride (5a) in presence of an ion exchange resin, t...  
WO/2018/129230A1
Synthetic methods for the preparation of ligands and metal-ligand complexes are disclosed.  
WO/2018/126040A1
The present invention is generally directed to crystalline forms of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-me thyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcy clohexanol and processes for their preparation.  
WO/2018/124148A1
The purpose of the present invention relates to providing a novel glyceric acid ester which can be produced at a high yield and for which use as a synthesis intermediate can be expected, and a method for producing same. The purpose of th...  
WO/2018/124149A1
The purpose of the present invention is to provide a method for producing glyceric acid ester that enables easy, high-yield production and makes it easy to reuse pyridines that are used for a reaction. Provided is a method for producing ...  
WO/2018/124147A1
The present invention relates to a method for manufacturing 1,3-dioxane-5-ones by a short and simple method from raw materials that can be obtained easily and inexpensively, using 1,3-dioxane, which is a mixture with 1,3-dioxalans, as a ...  
WO/2018/113581A1
Disclosed are a conjugate of dezocine and polyethylene glycol and a pharmaceutical composition thereof, wherein same have better pharmacokinetical properties and a high drug absorption degree, can decrease the side effects of drugs, and ...  
WO/2018/119263A1
Disclosed are compounds of Formula (I'), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing o...  
WO/2018/108797A1
The invention relates primarily to a method for producing L-glufosinate or the salts thereof using ephedrine, in particular for producing L-glufosinate or the salts thereof by (dynamic kinetic) resolution of racemates. The invention also...  
WO/2018/108888A1
The invention pertains to a process for preparing hydroxyethyl ethylene amines and/or ethylene urea derivatives thereof comprising the step of reacting monoethylene glycol with an amine-functional compound comprising at least two -NH- un...  
WO/2018/108794A1
The invention relates to a method for producing D-glufosinate or salts thereof using ephedrine, in particular for producing D-glufosinate or salts thereof by (dynamic kinetic) resolution of racemates. The invention also relates to certai...  
WO/2018/108698A1
The invention relates to a method for producing ethanolamines and/or ethyleneamines in the gas phase by reacting ethylene glycol with ammonia in the presence of an amination catalyst. The method is characterized in that the amination cat...  
WO/2018/104176A1
The invention relates to a method for producing farnesyl amines by reacting ß-farnesene with one or more amines in the presence of a transition metal catalyst of the10th subgroup, at a temperature in the region of between 60 - 150 °C. (I)  
WO/2018/090982A1
Provided are a benzodicycloalkane derivative, and a preparation method and use thereof. In particular, provided is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method th...  
WO/2018/067685A1
Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.  
WO/2018/064476A1
Crystalline 2-hydroxy-N,N-dimethylethanaminium 1 -(2-(5-(tert-butyl) -thiophene-2-carboxamido)-3-(4-(5-(4'-ethyl-[1,1'-bi(cyclohe xan)]-3- en-4-yl)pyrimidin-2-yl)phenyl)propanoyl)azetidine-3-carboxyl ate salt, and methods related to synt...  
WO/2018/048932A1
Methods and compositions for use in treating, preventing or improving diseases related to the liver in an animal, including but not limited to nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) or nonalcoholic steato...  
WO/2018/044982A1
A process for preparing a silver-containing catalyst for the selective oxidation of ethylene to ethylene oxide including the steps of: (a) providing a multimodal support, (b) preparing an impregnation solution comprising a silver compone...  
WO/2018/028679A1
A post-processing method for a Mirabegron intermediate, comprising the following steps: with a Mirabegron carbonyl of formula I serving as a reaction raw material, the carbonyl therein is reduced via a reduction reaction under the effect...  
WO/2018/022871A1
Embodiments are directed to terphenyl ligands and metal complex formed therefrom, wherein the metal complexes are used as procatalyst in polyolefin polymerization and comprise the following structure:  
WO/2018/009720A1
Methods and compounds for use in promoting survival of at least one eukaryotic cell, wherein the compounds are effective as gamma-ketoaldehyde scavengers.  
WO/2018/000098A1
A method of treating an inflammatory myopathy includes topically administering to the skin of an individual with the inflammatory myopathy a composition comprising R-salbutamol, a physiologically acceptable derivative thereof, or a pharm...  
WO/2018/004945A1
A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO by providing a composition comprising a compound set forth in Formula (I):  
WO/2017/218886A1
The invention relates to compounds, compositions and methods for activating, reactivating, reversing or preventing the deactivation of cholinesterases, such as acetylcholinesterase and butyrylcholinesterase.  
WO/2017/214680A1
The present invention relates to new multi-functional compounds that are useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease, to the preparation of the compounds, and to compositions including the compounds...  
WO/2017/215592A1
The present disclosure provides co-crystals of a lithium benzoatecompound and a co-former compound of Formula (I). Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a ...  
WO/2017/212007A1
Compositions for nucleic acid delivery are provided which comprise a relatively low amount a permanently cationic lipid or lipidoid, such as a lipid comprising a quaternary ammonium group. The compositions are suitable for the delivery o...  
WO/2017/214334A1
Disclosed herein are lignin-derived ionic liquids and methods for preparing them. The methods include forming a reaction mixture comprising a lignin-derived starting material, a carbonyl compound, and an amine; maintaining the reaction m...  
WO/2017/212009A1
A composition for the delivery of a nucleic acid compound is provided which comprises a cationic peptide or polymer and a lipidoid compound. The nucleic acid compound may be any chemically modified or unmodified DNA or RNA. The amount of...  
WO/2017/207839A1
The invention relates to a method for obtaining β-amino alcohols, in which the following steps are performed using amines and a diol/water mixture: adding a catalytic mixture to the starting amine; next, adding the diol/water mixture; s...  
WO/2017/206692A1
An organic amine salt compound having the general formula (I): An-[Bm+]p. In the formula, An- is anions having -n valence serving as CO2 donors, wherein n = 1, 2, or 3; Bm+ is or contains: ammonium ions and/or organic amine B cations; m ...  
WO/2017/206693A1
An organic amine salt compound having the general formula (I): An-[Bm+]p. In the formula, An- is anions having -n valence serving as CO2 donors, wherein n = 1, 2, or 3; Bm+ is or contains: ammonium ions, hydrazine ions and/or organic ami...  
WO/2017/209235A1
The present invention addresses the problem of providing a low-cost and highly-safe method for producing a polycyclic aromatic aminophenol compound in a small number of steps. The method for producing a polycyclic aromatic aminophenol co...  
WO/2017/197014A2
Compositions comprising a polymeric dye and a cyclodextrin are provided. Methods associated with preparation and use of such compounds, for example in methods for detection of any analyte molecule, are also provided.  
WO/2017/193913A1
Provided are a fosaprepitant phosphate intermediate (IV) preparation method, a fosaprepitant phosphate intermediate (IV-A) and a method (AA) for preparing fosaprepitant dimeglumine by using the intermediate (IV-A). IV: R1 and R2 are inde...  
WO/2017/185261A1
The present invention relates to the technical field of medicine, and provides mosapride active metabolites (R)-N-[2-hydroxy-3-(4-fluorobenzyl)amino]propyl-5-chloro-4-a mino-2-ethoxy benzamide (levo isomer) and (S)-N-[2-hydroxy-3-(4-fluo...  
WO/2017/182438A1
The present invention relates to tapentadol phosphate in crystalline form and to a process for producing tapentadol phosphate in crystalline form. Further,the present invention relates to a composition comprising crystalline tapentadol p...  
WO/2017/177065A2
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Meth...  
WO/2017/173355A1
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Meth...  
WO/2017/173348A1
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, L5, A, M, m and n are as defined herei...  
WO/2017/159814A1
The present invention provides a method for producing ethanolamines whereby it is possible to keep the yield of dialkanolamines low (for example, less than 30% by weight). This method for producing alkanolamines involves reacting an alky...  
WO/2017/152083A1
Processes are described for the preparation of F-benzoxazinorifamycin I: and intermediates for conjugation with an antibody.  

Matches 251 - 300 out of 5,852